BPI Ask the Expert Webinar: Designing Robust CHO Cell Line Strategies for Accelerated Clinical Progression
September 3, 2026
11 am EDT | 8 am PDT | 5 pm CEST
Duration: 30 minutes
Designing Robust CHO Cell Line Strategies for Accelerated Clinical Progression
Dennis Lin, PhD
Associate Director, Cell Line and Cell Culture Process Development
Abstract
As biologics pipelines become more complex and development timelines continue to compress, CHO cell line development strategies must support both speed and long-term manufacturing confidence. This webcast will introduce key considerations for designing robust CHO cell line development strategies that help accelerate progression toward clinical milestones while reducing downstream development risk.
Explore how integration strategy, clone stability, early productivity assessment, and representative product quality can influence the success of a biologics program from early development through process scale-up. Drawing on Bora Biologics’ approach to CHO cell line development, the webcast will discuss how flexible platform selection, including site-specific and transposon-based integration strategies, can help align cell line development workflows with molecule complexity, program timelines, and manufacturability requirements.
Attendees will gain a high-level understanding of how strategic CHO cell line design can support faster decision-making, improve development predictability, and create a stronger foundation for clinical progression. Themes explored in greater depth during the full presentation include platform comparison, case study insights, and the role of dual-strategy integration frameworks in de-risking cell line development.
Key Takeaways
- Why CHO cell line strategy is becoming increasingly important as biologics timelines accelerate.
- How integration platform selection can impact speed, stability, productivity, and product quality.
- The role of representative cell pools in enabling earlier development decisions.
- How flexible CLD frameworks can help reduce risk for complex biologics programs.
- What sponsors should consider when aligning CLD strategy with clinical progression goals.
Presenter Bio
Dennis Lin, Ph.D., is a bioprocess development leader with extensive experience advancing therapeutic biologics from cell line development and GMP cell banking through upstream process development and scale-up up to 2,000 L. He currently serves as Associate Director, Cell Line and Cell Culture Process Development at Bora Biologics, where he leads CLD and CCPD strategy and supports IND-enabling CMC execution through cross-functional collaboration and CDMO partnerships. His expertise spans CHO, SP2/0, and NK cell platforms, with experience across more than 30 projects and diverse modalities including monoclonal antibodies, bispecific antibodies, complex proteins, biosimilars, and cell therapy. Prior to joining Bora Biologics, Dennis held roles at China Innovation Center of Roche, Canton Biologics, Lonza, Thermo Fisher Scientific, and Mycenax, where he contributed across GMP cell banking, upstream development, bioproduction applications, and commercial strategy. He earned his Ph.D. in Bioinformatics and Structural Biology from National Tsing Hua University, Taiwan.
